Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176058 | 1.00 | RORC (0.35) | RORCSTSADORA1SLC2A1NR1H2 | |
| SCHEMBL16422844 | 0.88 | STS (0.35) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL19168628 | 0.84 | RORC (0.38) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL2256948 | 0.83 | NR1H2 (0.40) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL23538445 | 0.81 | RORC (0.37) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL5809590 | 0.78 | RORC (0.37) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL16434814 | 0.76 | RORC (0.33) | RORCSTSHTR6PDK4 | |
| SCHEMBL25322322 | 0.76 | NR1H2 (0.35) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL21111699 | 0.75 | RORC (0.34) | RORCSTSNR1H2HTR6PDK4 | |
| SCHEMBL21111698 | 0.75 | RORC (0.34) | RORCSTSNR1H2HTR6PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-4086249-A2 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Trevena, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114773318-A | Delta opioid receptor modulating compounds containing six-membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-108025002-B | Delta opioid receptor modulating compounds containing six membered azaheterocycles, methods of use and preparation thereof | 特维娜有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3344248-B1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465980-B2 | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | RORC 139/4885STS 4599/4885ADORA1 192/4885 |
| US-20230203002-A1 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | RORC 139/4885STS 4599/4885ADORA1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.